Leerink Partnrs Estimates Bruker's Q2 Earnings (NASDAQ:BRKR)

Key Points

• Leerink Partnrs revised Bruker's Q2 2026 earnings per share (EPS) estimate down from $0.51 to $0.45, while the consensus estimate for the current full year is $2.69 per share.
• Bruker recently reported $0.32 EPS for the last quarter, which was $0.01 below analysts' expectations, alongside a revenue of $797.40 million.
• The company declared a quarterly dividend of $0.05, with a current yield of 0.6%, and an annualized dividend payout ratio of 38.46%.

Bruker Corporation (NASDAQ:BRKR - Free Report) - Research analysts at Leerink Partnrs dropped their Q2 2026 earnings per share (EPS) estimates for Bruker in a research report issued on Monday, October 13th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings per share of $0.45 for the quarter, down from their prior forecast of $0.51. The consensus estimate for Bruker's current full-year earnings is $2.69 per share.

Other analysts also recently issued reports about the company. Stifel Nicolaus set a $40.00 price objective on Bruker and gave the company a "hold" rating in a report on Tuesday, August 5th. Bank of America decreased their price objective on Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Jefferies Financial Group set a $60.00 target price on shares of Bruker and gave the stock a "buy" rating in a report on Monday, August 4th. Wells Fargo & Company reduced their target price on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a report on Tuesday, August 5th. Finally, Citigroup dropped their price target on Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a research note on Monday, August 4th. Five research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $51.00.

Bruker Stock Performance

BRKR stock opened at $36.20 on Thursday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. The business has a 50-day moving average price of $33.21 and a 200 day moving average price of $37.06. The company has a market capitalization of $5.49 billion, a P/E ratio of 69.62, a PEG ratio of 5.11 and a beta of 1.20. Bruker has a 1-year low of $28.53 and a 1-year high of $64.64.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The business had revenue of $797.40 million during the quarter, compared to analysts' expectations of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business's revenue for the quarter was down .4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.52 EPS. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC raised its stake in shares of Bruker by 377.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company's stock worth $25,000 after buying an additional 487 shares during the period. Pinnacle Bancorp Inc. acquired a new position in shares of Bruker during the 1st quarter worth approximately $29,000. Huntington National Bank raised its stake in shares of Bruker by 750.0% during the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company's stock worth $30,000 after buying an additional 645 shares during the period. Allworth Financial LP raised its stake in Bruker by 92.4% in the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after purchasing an additional 364 shares during the last quarter. Finally, Spire Wealth Management acquired a new position in Bruker in the 2nd quarter valued at $32,000. 79.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Bruker news, Director Cynthia M. Friend sold 3,535 shares of the company's stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $32.25, for a total value of $114,003.75. Following the sale, the director owned 18,016 shares in the company, valued at approximately $581,016. This represents a 16.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 27.30% of the company's stock.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd were given a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.6%. The ex-dividend date was Tuesday, September 23rd. Bruker's dividend payout ratio is currently 38.46%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.